Trial
NCT01990352
Correlate BRCA1 Protein Expression With Response to DNA Damaging Chemotherapy
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
University of Arizona
Collaborators
—
Condition
Breast Cancer
Intervention
Pegylated liposomal doxorubicin
Why stopped
The PI determined that study specimens being obtained did not yield sufficient data to analyze the prespecified outcome measures and decided to terminate the study prior to meeting enrollment goals.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2023-11-21